Propargylamine: an important moiety in drug discovery - Supplementary Figures
Supplementary Figure 1. Chemical structures of the FDA-approved drugs rasagiline and
Supplementary Figure 2. Metabolic pathways that propargylamine derivatives may undergo within the
body according to different publications in the literature [8,9].
Supplementary Figure 3. Proposed mechanism of activation of propargylamine-based MAO inhibitors by
Albreht et al. .
Supplementary Figure 4. Propargylamine-based radioligands for PET imaging of MAO-A and MAO-B
highlighted in the work by Narayanaswami et al. .
Supplementary Figure 5. Chemical structure of ladostigil, a propargylamine-based clinical candidate that
acts as a MAO and AChE–BuChE dual inhibitor.
Supplementary Figure 6. General scheme of the copper-catalyzed azide–alkyne cycloaddition (CuAAC),
one of the most used bioorthogonal click chemistry reactions .